mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.
Company profile
Ticker
VTRS, 0A5V
Exchange
Website
CEO
Michael Goettler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Upjohn Inc
SEC CIK
Corporate docs
Subsidiaries
Agila Australasia Pty Ltd • Alphapharm Pty. Ltd. • Mylan Australia Holding Pty Ltd • Mylan Australia Pty Limited • Upjohn Australia Pty Ltd • Viatris Pty. Ltd. • Arcana Arzneimittel GmbH • Mylan Österreich GmbH • Viatris GX BV • Viatris BV ...
IRS number
834364296
VTRS stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results
28 Feb 24
8-K/A
Entry into a Material Definitive Agreement
30 Jan 24
8-K/A
Departure of Directors or Certain Officers
15 Dec 23
8-K
Departure of Directors or Certain Officers
15 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Robert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders
15 Dec 23
DEFA14A
Additional proxy soliciting materials
24 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
VTRS
Earnings call transcript
2023 Q3
7 Nov 23
VTRS
Earnings call transcript
2023 Q2
7 Aug 23
VTRS
Earnings call transcript
2023 Q1
8 May 23
VTRS
Earnings call transcript
2022 Q4
27 Feb 23
VTRS
Earnings call transcript
2022 Q3
7 Nov 22
VTRS
Earnings call transcript
2022 Q2
8 Aug 22
VTRS
Earnings call transcript
2022 Q1
9 May 22
VTRS
Earnings call transcript
2021 Q4
28 Feb 22
VTRS
Earnings call transcript
2021 Q3
8 Nov 21
VTRS
Earnings call transcript
2021 Q2
9 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
57.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 790 |
Opened positions | 97 |
Closed positions | 229 |
Increased positions | 211 |
Reduced positions | 337 |
13F shares | Current |
---|---|
Total value | 6.46 tn |
Total shares | 683.43 mm |
Total puts | 1.08 mm |
Total calls | 2.24 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 142.26 mm | $1.54 tn |
Davis Selected Advisers | 62.66 mm | $678.63 bn |
STT State Street | 61.92 mm | $670.64 bn |
T. Rowe Price | 49.47 mm | $535.72 mm |
IVZ Invesco | 30.14 mm | $326.45 bn |
Pacer Advisors | 20.85 mm | $225.84 bn |
Camber Capital Management | 18.50 mm | $200.36 mm |
Slate Path Capital | 15.24 mm | $165.01 bn |
MS Morgan Stanley | 13.23 mm | $143.32 bn |
Dimensional Fund Advisors | 12.20 mm | $132.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Goff Corinne Le | RSU Common Stock | Grant | Acquire A | No | No | 0 | 110,162 | 0.00 | 110,162 |
18 Apr 24 | Goff Corinne Le | RSU Common Stock | Grant | Acquire A | No | No | 0 | 78,688 | 0.00 | 78,688 |
2 Apr 24 | Rajiv Malik | RSU Common Stock | Grant | Acquire A | No | No | 0 | 18,845 | 0.00 | 18,845 |
13 Mar 24 | Anthony Mauro | Common Stock | Sell | Dispose S | No | No | 12.0948 | 250,000 | 3.02 mm | 243,044 |
4 Mar 24 | Theodora Mistras | RSU Common Stock | Grant | Acquire A | No | No | 0 | 93,447 | 0.00 | 93,447 |
News
Piper Sandler Reiterates Neutral on Viatris, Raises Price Target to $13
28 Mar 24
Looking Into Viatris's Recent Short Interest
15 Mar 24
Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?
28 Feb 24
Viatris Q4 Adjusted EPS $0.62 Misses $0.65 Estimate, Sales $3.83B Miss $3.87B Estimate
28 Feb 24
Earnings Scheduled For February 28, 2024
28 Feb 24
Press releases
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
16 Apr 24
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
15 Apr 24
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
27 Mar 24
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
11 Mar 24
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
28 Feb 24